Moderna prepares for the “commercial launch” of its vaccine.
Modern biotechnology begins the procedures to request the authorization of its experimental vaccine against Covid-19, one of the most advanced in the world. The biotech company reported this Wednesday that it has received from the European Medicines Agency (EMA) confirmation that its candidate is eligible to submit a marketing authorization application in the European Union.
Moderna’s candidate is one of 10 currently in phase III clinical studies, the last stage before its commercialization in which its safety and efficacy are tested. The request for authorization by the biotech will include updated clinical information on its mRNA-1273 product, according to the company.
The approval of Moderna’s vaccine would mean that a large part of the production would come from Spain, since it signed a manufacturing agreement with Laboratorios Rovi to fill the vaccine in Madrid, in addition to other agreements in Europe with the Swiss company Lonza.
The EMA has already announced in recent days that it has started a process of continuous evaluation of the Pfizer and AstraZeneca vaccines, the two most advanced in the race to get approval in the European Union.